journal article·2015-09Open access

Bridging the lesion—engineering a permissive substrate for nerve regeneration

Liliana R. Pires, Ana P. Pêgo

Regenerative Biomaterials· Volume 2· Issue 3

Abstract

Biomaterial-based strategies to restore connectivity after lesion at the spinal cord are focused on bridging the lesion and providing an favourable substrate and a path for axonal re-growth. Following spinal cord injury (SCI) a hostile environment for neuronal cell growth is established by the activation of multiple inhibitory mechanisms that hamper regeneration to occur. Implantable scaffolds can provide mechanical support and physical guidance for axon re-growth and, at the same time, contribute to alleviate the hostile environment by the in situ delivery of therapeutic molecules and/or relevant cells. Basic research on SCI has been contributing with the description of inhibitory mechanisms for regeneration as well as identifying drugs/molecules that can target inhibition. This knowledge is the background for the development of combined strategies with biomaterials. Additionally, scaffold design is significantly evolving. From the early simple hollow conduits, scaffolds with complex architectures that can modulate cell fate are currently being tested. A number of promising pre-clinical studies combining scaffolds, cells, drugs and/or nucleic acids are reported in the open literature. Overall, it is considered that to address the multi-factorial inhibitory environment of a SCI, a multifaceted therapeutic approach is imperative. The progress in the identification of molecules that target inhibition after SCI and its combination with scaffolds and/or cells are described and discussed in this review.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nerve injury and regeneration · Spinal Cord Injury Research · Neurogenesis and neuroplasticity mechanisms

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (99)

Show source-provided references
1. 10.1016/j.pneurobio.2005.12.00410.1016/j.pneurobio.2005.12.004 ↗
2. 10.1038/sj.sc.310171510.1038/sj.sc.3101715 ↗
3. 10.3171/FOC.2008.25.11.E210.3171/FOC.2008.25.11.E2 ↗
4. 10.1016/j.neulet.2012.02.02510.1016/j.neulet.2012.02.025 ↗
5. 10.1126/science.617103410.1126/science.6171034 ↗
6. 10.1007/BF0114832410.1007/BF01148324 ↗
7. 10.1038/nn119510.1038/nn1195 ↗
8. 10.1016/j.expneurol.2007.05.01410.1016/j.expneurol.2007.05.014 ↗
9. Restorative surgery of the central nervous system by means of tissue engineering using Neurogen implants10.1007/PL00021694 ↗
10. 10.1007/s11706-012-0157-510.1007/s11706-012-0157-5 ↗
11. 10.1016/j.jocn.2012.03.00210.1016/j.jocn.2012.03.002 ↗
12. 10.1042/cs094055710.1042/cs0940557 ↗
13. 10.1056/NEJM19900517322200110.1056/NEJM199005173222001 ↗
14. 10.1038/sj.sc.310098610.1038/sj.sc.3100986 ↗
15. 10.1038/ncpneuro022110.1038/ncpneuro0221 ↗
16. 10.1016/j.spinee.2003.07.00710.1016/j.spinee.2003.07.007 ↗
17. Effect of intravenous corticosteroids on death within 14 days in 10 008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet 2004;364:1321-8.10.1016/S0140-6736(04)17188-2 ↗
18. 10.1016/j.msec.2014.05.02510.1016/j.msec.2014.05.025 ↗
19. 10.1016/j.biomaterials.2008.12.07710.1016/j.biomaterials.2008.12.077 ↗
20. 10.1016/j.biomaterials.2008.01.00210.1016/j.biomaterials.2008.01.002 ↗
21. 10.1523/JNEUROSCI.5547-07.200810.1523/JNEUROSCI.5547-07.2008 ↗
22. 10.1016/j.neuroscience.2009.04.01610.1016/j.neuroscience.2009.04.016 ↗
23. 10.1016/j.expneurol.2007.06.00910.1016/j.expneurol.2007.06.009 ↗
24. 10.1016/S0003-9993(97)90008-310.1016/S0003-9993(97)90008-3 ↗
25. 10.1523/JNEUROSCI.3444-07.200710.1523/JNEUROSCI.3444-07.2007 ↗
26. 10.1006/exnr.1999.711810.1006/exnr.1999.7118 ↗
27. 10.1016/j.neuroscience.2008.12.01310.1016/j.neuroscience.2008.12.013 ↗
28. 10.1016/j.immuni.2013.02.01210.1016/j.immuni.2013.02.012 ↗
29. 10.1038/nm0798-81410.1038/nm0798-814 ↗
30. 10.1016/j.it.2004.09.01510.1016/j.it.2004.09.015 ↗
31. 10.1038/nri244810.1038/nri2448 ↗
32. 10.1002/glia.2277410.1002/glia.22774 ↗
33. 10.1523/JNEUROSCI.3257-09.200910.1523/JNEUROSCI.3257-09.2009 ↗
34. 10.1038/nrn239810.1038/nrn2398 ↗
35. 10.1006/exnr.1999.717310.1006/exnr.1999.7173 ↗
36. 10.1016/j.cytogfr.2012.08.00810.1016/j.cytogfr.2012.08.008 ↗
37. 10.1089/08977150377019586710.1089/089771503770195867 ↗
38. 10.1523/JNEUROSCI.5275-03.200410.1523/JNEUROSCI.5275-03.2004 ↗
39. 10.1093/brain/aws07210.1093/brain/aws072 ↗
40. United States National Institutes of Health. Clinical Trials.gov. http://www.clinicaltrials.gov/ (June 2015, date last accessed).
41. 10.1083/jcb.20030108010.1083/jcb.200301080 ↗
42. Oligodendrocytes and CNS myelin are nonpermissive substrates for neurite growth and fibroblast spreading in vitro10.1523/JNEUROSCI.08-07-02381.1988 ↗
43. 10.1146/annurev.neuro.26.010302.08113910.1146/annurev.neuro.26.010302.081139 ↗
44. Nogo-A and myelin-associated glycoprotein mediate neurite growth inhibition by antagonistic regulation of RhoA and Rac110.1523/JNEUROSCI.22-23-10368.2002 ↗
45. 10.1146/annurev.bioeng.5.011303.12073110.1146/annurev.bioeng.5.011303.120731 ↗
46. 10.1038/sc.2012.3910.1038/sc.2012.39 ↗
47. 10.1038/3500021910.1038/35000219 ↗
48. 10.1016/j.conb.2004.01.00410.1016/j.conb.2004.01.004 ↗
49. 10.1016/B978-0-12-407178-0.00007-710.1016/B978-0-12-407178-0.00007-7 ↗
50. 10.1517/13543784.2015.100962910.1517/13543784.2015.1009629 ↗
51. 10.1089/neu.2011.175210.1089/neu.2011.1752 ↗
52. Inactivation of rho signaling pathway promotes CNS axon regeneration10.1523/JNEUROSCI.19-17-07537.1999 ↗
53. 10.1089/neu.2006.23.30910.1089/neu.2006.23.309 ↗
54. 10.1089/neu.2011.176510.1089/neu.2011.1765 ↗
55. 10.1073/pnas.90.24.1169310.1073/pnas.90.24.11693 ↗
56. 10.1007/s10787-009-0016-x10.1007/s10787-009-0016-x ↗
57. 10.1523/JNEUROSCI.4353-06.200710.1523/JNEUROSCI.4353-06.2007 ↗
58. 10.1089/neu.2007.046410.1089/neu.2007.0464 ↗
59. 10.1016/j.expneurol.2013.06.02310.1016/j.expneurol.2013.06.023 ↗
60. 10.1016/j.bjps.2011.07.01410.1016/j.bjps.2011.07.014 ↗
61. 10.1016/j.expneurol.2013.11.00810.1016/j.expneurol.2013.11.008 ↗
62. 10.1007/s00441-012-1334-710.1007/s00441-012-1334-7 ↗
63. 10.1016/S0361-9230(99)00072-610.1016/S0361-9230(99)00072-6 ↗
64. 10.1016/S0166-2236(97)01139-910.1016/S0166-2236(97)01139-9 ↗
65. Reduction of neurite outgrowth in a model of glial scarring following CNS injury is correlated with the expression of inhibitory molecules on reactive astrocytes10.1523/JNEUROSCI.11-11-03398.1991 ↗
66. 10.1038/416636a10.1038/416636a ↗
67. 10.1016/j.expneurol.2007.11.00210.1016/j.expneurol.2007.11.002 ↗
68. 10.1016/j.expneurol.2007.05.00110.1016/j.expneurol.2007.05.001 ↗
69. 10.1016/S0014-4886(03)00383-210.1016/S0014-4886(03)00383-2 ↗
70. Lentiviral vectors express chondroitinase ABC in cortical projections and promote sprouting of injured corticospinal axons
71. 10.1016/j.expneurol.2015.05.02210.1016/j.expneurol.2015.05.022 ↗
72. 10.1016/S0959-4388(02)00372-010.1016/S0959-4388(02)00372-0 ↗
73. 10.1006/exnr.1996.013110.1006/exnr.1996.0131 ↗
74. 10.1046/j.1460-9568.1999.00809.x10.1046/j.1460-9568.1999.00809.x ↗
75. 10.1196/annals.1344.03610.1196/annals.1344.036 ↗
76. 10.1016/S0074-7742(02)50083-010.1016/S0074-7742(02)50083-0 ↗
77. 10.1016/j.jocn.2006.03.02310.1016/j.jocn.2006.03.023 ↗
78. 10.1089/neu.2009.117710.1089/neu.2009.1177 ↗
79. 10.1177/107385841351463510.1177/1073858413514635 ↗
80. 10.1016/j.pneurobio.2013.11.00210.1016/j.pneurobio.2013.11.002 ↗
81. 10.2174/156802661566615033011105710.2174/1568026615666150330111057 ↗
82. 10.1111/j.1582-4934.2012.01603.x10.1111/j.1582-4934.2012.01603.x ↗
83. 10.1016/j.neulet.2012.02.02810.1016/j.neulet.2012.02.028 ↗
84. Designing ideal conduits for peripheral nerve repair10.3171/FOC.2009.26.2.E5 ↗
85. 10.1098/rsif.2011.043810.1098/rsif.2011.0438 ↗
86. Aligned electrospun nanofibers specify the direction of dorsal root ganglia neurite growth10.1002/jbm.a.31285 ↗
87. 10.1016/j.biomaterials.2008.12.05110.1016/j.biomaterials.2008.12.051 ↗
88. 10.1016/j.biomaterials.2008.05.01410.1016/j.biomaterials.2008.05.014 ↗
89. 10.1016/j.biomaterials.2009.11.01310.1016/j.biomaterials.2009.11.013 ↗
90. 10.1016/j.biomaterials.2009.05.01110.1016/j.biomaterials.2009.05.011 ↗
91. 10.1163/15685620174443410.1163/156856201744434 ↗
92. 10.1016/S0168-3659(02)00351-610.1016/S0168-3659(02)00351-6 ↗
93. 10.1002/adfm.20060044110.1002/adfm.200600441 ↗
94. 10.3171/JNS/2008/109/8/029410.3171/JNS/2008/109/8/0294 ↗
95. 10.1371/journal.pone.008859310.1371/journal.pone.0088593 ↗
96. 10.1002/mabi.20050015110.1002/mabi.200500151 ↗
97. 10.1016/j.bbrc.2007.04.04910.1016/j.bbrc.2007.04.049 ↗
98. 10.1016/j.actbio.2012.10.02910.1016/j.actbio.2012.10.029 ↗
99. 10.1089/ten.tea.2011.043010.1089/ten.tea.2011.0430 ↗